A preliminary analysis of association between the down-regulation of microRNA-181b expression and symptomatology improvement in schizophrenia patients before and after antipsychotic treatment

Journal of Psychiatric Research

Volumn 54, Issue 1, 2014, Pages 134-140

  Song, Hong tao ^a   Sun, Xin yang ^b,c   Zhang, Liang ^d   Zhao, Lin ^e   Guo, Zhong min ^f   Fan, Hui min ^b   Zhong, Ai fang ^c   Niu, Wei ^c   Dai, Yun hua ^f   Zhang, Li yi ^c   Shi, Zheng ^c   Liu, Xiao ping ^f   Lu, Jim ^f  

^a BENGBU MEDICAL COLLEGE   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c Prevention and Treatment Center for Psychological Diseases   (China)

^d Medical Department   (China)

^e Department of Psychiatry   (China)

^f GoPath Laboratories LLC   (United States)

Author keywords

Antipsychotics; MicroRNA; PANSS; Schizophrenia; Symptomatology

Indexed keywords

MICRORNA; MICRORNA 132; MICRORNA 181B; MICRORNA 195; MICRORNA 212; MICRORNA 30E; MICRORNA 346; MICRORNA 34A; MICRORNA 432; MICRORNA 7; OLANZAPINE; QUETIAPINE; RISPERIDONE; UNCLASSIFIED DRUG; ZIPRASIDONE; NEUROLEPTIC AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG RESPONSE; FEMALE; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION; HUMAN; MALE; MENTAL PATIENT; NEGATIVE SYNDROME; OUTCOME ASSESSMENT; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHIZOPHRENIA; SCORING SYSTEM; SYMPTOMATOLOGY; ADOLESCENT; CASE CONTROL STUDY; DRUG EFFECTS; GENETICS; METABOLISM; MIDDLE AGED; NONPARAMETRIC TEST; PSYCHOLOGICAL RATING SCALE; RECEIVER OPERATING CHARACTERISTIC; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; CASE-CONTROL STUDIES; DOWN-REGULATION; FEMALE; HUMANS; MALE; MICRORNAS; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; ROC CURVE; SCHIZOPHRENIA; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84899896406     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2014.03.008     Document Type: Article

References (49)

1. Benes F.M., Berretta S. GABAergic interneurons: implications for understanding schizophrenia and bipolar disorder. Neuropsychopharmacology 2001, 25:1-27.
2. Beveridge N., Gardiner E., Carroll A., Tooney P., Cairns M. Schizophrenia is associated with an increase in cortical microRNA biogenesis. Mol Psychiatry 2009, 15:1176-1189.
3. Beveridge N.J., Cairns M.J. MicroRNA dysregulation in schizophrenia. Neurobiology Disease 2012, 46:263-271.
4. Beveridge N.J., Tooney P.A., Carroll A.P., Gardiner E., Bowden N., Scott R.J., et al. Dysregulation of miRNA 181b in the temporal cortex in schizophrenia. Hum Mol Genet 2008, 17:1156-1168.
5. Bocchio-Chiavetto L., Maffioletti E., Bettinsoli P., Giovannini C., Bignotti S., Tardito D., et al. Blood microRNA changes in depressed patients during antidepressant treatment. Eur Neuropsychopharmacol 2013, 23:602-611.
6. Cardno A.G., Gottesman I.I. Twin studies of schizophrenia: from bow-and-arrow concordances to star wars Mx and functional genomics. Am Journal Medical Genetics 2000, 97:12-17.
7. Chen H., Wang N., Burmeister M., McInnis M.G. MicroRNA expression changes in lymphoblastoid cell lines in response to lithium treatment. Int J Neuropsychopharmacol 2009, 12:975.
8. Dinan T.G. MicroRNAs as a target for novel antipsychotics: a systematic review of an emerging field. Int J Neuropsychopharmacol 2010, 13:395.
9. Ding X.C., Weiler J., Großhans H. Regulating the regulators: mechanisms controlling the maturation of microRNAs. Trends Biotechnol 2009, 27:27-36.
10. Filipowicz W., Bhattacharyya S.N., Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight?. Nat Rev Genet 2008, 9:102-114.
11. Friedman R.C., Farh K.K.-H., Burge C.B., Bartel D.P. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009, 19:92-105.
12. Gardiner E., Beveridge N., Wu J., Carr V., Scott R., Tooney P., et al. Imprinted DLK1-DIO3 region of 14q32 defines a schizophrenia-associated miRNA signature in peripheral blood mononuclear cells. Mol Psychiatry 2011, 17:827-840.
13. Garzya V., Forbes I.T., Gribble A.D., Hadley M.S., Lightfoot A.P., Payne A.H., et al. Studies towards the identification of a new generation of atypical antipsychotic agents. Bioorganic Med Chem Letter 2007, 17:400-405.
14. Gogos J.A., Gerber D.J. Schizophrenia susceptibility genes: emergence of positional candidates and future directions. Trends Pharmacol Sciences 2006, 27:226-233.
15. Greenwood T.A., Braff D.L., Light G.A., Cadenhead K.S., Calkins M.E., Dobie D.J., et al. Initial heritability analyses of endophenotypic measures for schizophrenia: the consortium on the genetics of schizophrenia. Arch Gen Psychiatry 2007, 64:1242.
16. Hunsberger J.G., Austin D.R., Chen G., Manji H.K. MicroRNAs in mental health: from biological underpinnings to potential therapies. Neuromolecular Med 2009, 11:173-182.
17. John B., Enright A.J., Aravin A., Tuschl T., Sander C., Marks D.S. Human microRNA targets. PLoS Biol 2004, 2:e363.
18. Kay S.R., Fiszbein A., Opler L.A. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987, 13:261-276.
19. Kocerha J., Faghihi M.A., Lopez-Toledano M.A., Huang J., Ramsey A.J., Caron M.G., et al. MicroRNA-219 modulates NMDA receptor-mediated neurobehavioral dysfunction. Proc Natl Acad Sci 2009, 106:3507-3512.
20. Kosik K.S. The neuronal microRNA system. Nat Rev Neurosci 2006, 7:911-920.
21. Kirchevsky A.M., King K.S., Donahue C.P., Khrapko K., Kosik K.S. A microRNA array reveals extensive regulation of microRNAs during brain development. Rna 2003, 9:1274-1281.
22. Kroh E.M., Parkin R.K., Mitchell P.S., Tewari M. Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). Methods 2010, 50:298-301.
23. Kuzman M.R., Medved V., Terzic J., Krainc D. Genome-wide expression analysis of peripheral blood identifies candidate biomarkers for schizophrenia. J Psychiatric Res 2009, 43:1073-1077.
24. Lai C.Y., Yu S.L., Hsieh M.H., Chen C.H., Chen H.Y., Wen C.C., et al. MicroRNA expression aberration as potential peripheral blood biomarkers for schizophrenia. PLoS One 2011, 6:e21635.
25. Lewis B.P., Burge C.B., Bartel D.P. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005, 120:15-20.
26. Lewis D.A., Gonzalez-Burgos G. Pathophysiologically based treatment interventions in schizophrenia. Nat Med 2006, 12:1016-1022.
27. Liu J., Carmell M.A., Rivas F.V., Marsden C.G., Thomson J.M., Song J.J., et al. Argonaute2 is the catalytic engine of mammalian RNAi. Science 2004, 305:1437-1441.
28. Liu S., Lu Z., Deng H., Zhao J.P., Yu X., Yuan Y.B., et al. MiRNA-365 and miRNA-520c-3p respond to risperidone treatment in first-episode schizophrenia after a 1 year remission. Chin Med J 2013, 126(14):2676-2680.
29. McGuffin P., Owen M.J., O'Donovan M.C., Thapar A., Gottesman I. Seminars in psychiatric genetics. BMJ 1994, 309:818.
30. Mellios N., Huang H.S., Baker S.P., Galdzicka M., Ginns E., Akbarian S. Molecular determinants of dysregulated GABAergic gene expression in the prefrontal cortex of subjects with schizophrenia. Biol Psychiatry 2009, 65:1006-1014.
31. Miller B.H., Wahlestedt C. MicroRNA dysregulation in psychiatric disease. Brain Res 2010, 1338:89-99.
32. Perkins D.O., Jeffries C.D., Jarskog L.F., Thomson J.M., Woods K., Newman M.A., et al. microRNA expression in the prefrontal cortex of individuals with schizophrenia and schizoaffective disorder. Genome Biol 2007, 8:R27.
33. Pierri J.N., Chaudry A.S., Woo T.-U.W., Lewis D.A. Alterations in chandelier neuron axon terminals in the prefrontal cortex of schizophrenic subjects. Am J Psychiatry 1999, 156:1709-1719.
34. Reynolds G.P., Beasley C.L. GABAergic neuronal subtypes in the human frontal cortex-development and deficits in schizophrenia. J Chem Neuroanatomy 2001, 22:95-100.
35. Ripke S., Sanders A.R., Kendler K.S., Levinson D.F., Sklar P., Holmans P.A., et al. Genome-wide association study identifies five new schizophrenia loci. Nat Gene 2011, 43:969.
36. Roth B.L., Sheffler D.J., Kroeze W.K. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov 2004, 3:353-359.
37. Saha S., Chant D., Welham J., McGrath J. A systematic review of the prevalence of schizophrenia. PLoS Med 2005, 2:e141.
38. Schratt G.M., Tuebing F., Nigh E.A., Kane C.G., Sabatini M.E., Kiebler M., et al. A brain-specific microRNA regulates dendritic spine development. Nature 2006, 439:283-289.
39. Sempere L.F., Freemantle S., Pitha-Rowe I., Moss E., Dmitrovsky E., Ambros V. Expression profiling of mammalian microRNAs uncovers a subset of brain-expressed microRNAs with possible roles in murine and human neuronal differentiation. Genome Biol 2004, 5:R13.
40. Shi W.T., Du J., Qi Y., Liang G., Wang T., Li S., et al. Aberrant expression of serum miRNAs in schizophrenia. J Psychiatry Res 2012, 46:198-204.
41. Shibata H., Tani A., Chikuhara T., Kikuta R., Sakai M., Ninomiya H., et al. Association study of polymorphisms in the group III metabotropic glutamate receptor genes, GRM4 and GRM7, with schizophrenia. Psychiatry Res 2009, 167:88-96.
42. Si T.M., Yang J.Z., Shu L., Wang X.L., Kong Q.M., Zhou M., et al. verification of validity and reliability of Positive and Negative Syndrome Scale (Chinese version). Chin J Ment Health 2004, 1:45-47.
43. Sullivan P.F., Kendler K.S., Neale M.C. Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies. Arch Gen Psychiatry 2003, 60:1187.
44. Thomson J.M., Parker J., Perou C.M., Hammond S.M. A custom microarray platform for analysis of microRNA gene expression. Nat Method 2004, 1:47-53.
45. Vo N., Klein M.E., Varlamova O., Keller D.M., Yamamoto T., Goodman R.H., et al. A cAMP-response element binding protein-induced microRNA regulates neuronal morphogenesis. Proc Natl Acad Sci U S A 2005, 102:16426-16431.
46. Wang Y., Zheng D., Tan Q., Wang M.X., Gu L.Q. Nanopore-based detection of circulating microRNAs in lung cancer patients. Nat Nanotechnol 2011, 6:668-674.
47. Xiberas X., Martinot J.L., Mallet L., Artiges E., Canal M., Loc'h C., et al. In vivo extrastriatal and striatal D2 dopamine receptor blockade by amisulpride in schizophrenia. J Clin Psychopharmacol 2001, 21:207-214.
48. Xiberas X., Martinot J.L., Mallet L., Artiges E., Loc'h C., Maziere B., et al. Extrastriatal and striatal D2 dopamine receptor blockade with haloperidol or new antipsychotic drugs in patients with schizophrenia. Br J Psychiatry 2001, 179:503-508.
49. Zhou R., Yuan P., Wang Y., Hunsberger J.G., Elkahloun A., Wei Y., et al. Evidence for selective microRNAs and their effectors as common long-term targets for the actions of mood stabilizers. Neuropsychopharmacology 2008, 34:1395-1405.